A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Biohaven Therapeutics Ltd.
- Study ID
- NCT06976268
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- BHV-8000 — DRUGBHV-8000 10 mg. Participants will take blinded investigational product (IP) once daily
- BHV-8000 — DRUGBHV-8000 20 mg. Participants will take blinded investigational product (IP) once daily
- Placebo — DRUGMatching placebo taken once daily
Study Details
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
Key Dates
- Start date
- May 28, 2025
- Status verified
- Jan 2026
- Primary completion
- Aug 31, 2027
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 550 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: BHV-8000 10 mg
- Experimental: BHV-8000 20 mg
- Placebo Comparator: Placebo
Primary Outcome Measure
Time to first qualifying worsening event on Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II [ Time Frame: Up to 48 Weeks ]
Central Contacts
- Chief Medical Officer203-404-0410
Locations (15)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Site-049 | Birmingham | Alabama | 35294 | - |
| Site-041 | Los Angeles | California | 90033 | - |
| Site-031 | Farmington | Connecticut | 06030 | - |
| Site-028 | New Haven | Connecticut | 06510 | - |
| Site-038 | Atlantis | Florida | 33462 | - |
| Site-017 | Boca Raton | Florida | 33486 | - |
| Site-051 | Maitland | Florida | 32751 | - |
| Site-027 | Chicago | Illinois | 60611 | - |
| Site-071 | Boston | Massachusetts | 02114 | - |
| Site-015 | Farmington Hills | Michigan | 48334 | - |
| Site-044 | Chesterfield | Missouri | 63005 | - |
| Site-005 | New York | New York | 10021 | - |
| Site-091 | Portland | Oregon | 97210 | - |
| Site-043 | Round Rock | Texas | 78681 | - |
| Site-007 | Bellevue | Washington | 98007 | - |
Find similar trials in Birmingham, AL
By condition
By specialty
Related Studies
- Natural History Study of SynucleinopathiesRecruiting · NYU Langone Health · Boston, Massachusetts
- Effects of Stimulation Patterns of Deep Brain StimulationEnrolling By Invitation · Duke University · Gainesville, Florida
- The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) SubstudyPHASE1/PHASE2 · Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
- North American Prodromal Synucleinopathy ConsortiumEnrolling By Invitation · Washington University School of Medicine · Sun City, Arizona